NASDAQ:SERA Sera Prognostics (SERA) Stock Price, News & Analysis $2.10 +0.05 (+2.44%) Closing price 04:00 PM EasternExtended Trading$2.10 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Sera Prognostics Stock (NASDAQ:SERA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sera Prognostics alerts:Sign Up Key Stats Today's Range$1.97▼$2.1850-Day Range$1.75▼$2.2952-Week Range$1.56▼$3.95Volume79,025 shsAverage Volume33,239 shsMarket Capitalization$82.24 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingModerate Buy Company Overview Sera Prognostics, Inc. is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery. Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test. The company has secured relevant regulatory clearances and reimbursement pathways, and continues to explore additional clinical applications for its proteomic platform. Collaborative efforts with academic institutions and health systems support ongoing studies aimed at demonstrating the test’s utility in diverse patient populations. Headquartered in Salt Lake City, Utah, Sera Prognostics is led by President and Chief Executive Officer Zachary Carr, who brings experience in commercializing diagnostic technologies. Under his leadership, the company has built a multidisciplinary team of professionals in molecular diagnostics, clinical operations, regulatory affairs, and market access. Sera Prognostics remains dedicated to advancing maternal–fetal health and expanding its footprint through partnerships with healthcare organizations and research sponsors.AI Generated. May Contain Errors. Read More Sera Prognostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreSERA MarketRank™: Sera Prognostics scored higher than 67% of companies evaluated by MarketBeat, and ranked 206th out of 832 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingSera Prognostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialSera Prognostics has a consensus price target of $5.50, representing about 161.9% upside from its current price of $2.10.Amount of Analyst CoverageSera Prognostics has only been the subject of 2 research reports in the past 90 days.Read more about Sera Prognostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sera Prognostics are expected to grow in the coming year, from ($0.58) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sera Prognostics is -3.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sera Prognostics is -3.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSera Prognostics has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sera Prognostics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.69% of the float of Sera Prognostics has been sold short.Short Interest Ratio / Days to CoverSera Prognostics has a short interest ratio ("days to cover") of 6.83.Change versus previous monthShort interest in Sera Prognostics has recently decreased by 8.27%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSera Prognostics does not currently pay a dividend.Dividend GrowthSera Prognostics does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.63 News SentimentSera Prognostics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Sera Prognostics this week, compared to 2 articles on an average week. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sera Prognostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $57,840.00 in company stock.Percentage Held by Insiders11.30% of the stock of Sera Prognostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.64% of the stock of Sera Prognostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sera Prognostics' insider trading history. Receive SERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SERA Stock News HeadlinesSERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026July 29 at 4:05 PM | prnewswire.comPRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CAREJuly 9, 2026 | prnewswire.comThe dollar just brokeBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this century — and the consequences for your savings and investments could be severe. President Trump has signed executive order 14241 to initiate the first full reset of the American dollar in 50 years. A new monetary anchor is being established — one that's not gold or crypto, but something far more unexpected that Vladimir Putin once called the key to world leadership.July 30 at 1:00 AM | Porter & Company (Ad)SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORSJune 30, 2026 | prnewswire.comSERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTHJune 24, 2026 | prnewswire.comSERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCYJune 23, 2026 | prnewswire.comSera Prognostics Holds 2026 Annual Stockholders MeetingJune 4, 2026 | tipranks.comSERA PROGNOSTICS ANNOUNCES BOARD TRANSITIONJune 1, 2026 | prnewswire.comSee More Headlines SERA Stock Analysis - Frequently Asked Questions How have SERA shares performed this year? Sera Prognostics' stock was trading at $2.95 at the beginning of 2026. Since then, SERA stock has decreased by 28.8% and is now trading at $2.10. How were Sera Prognostics' earnings last quarter? Sera Prognostics, Inc. (NASDAQ:SERA) issued its earnings results on Wednesday, May, 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. The business had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.07 million. Sera Prognostics had a negative net margin of 56,385.97% and a negative trailing twelve-month return on equity of 41.02%. Read the conference call transcript. When did Sera Prognostics IPO? Sera Prognostics (SERA) raised $75 million in an initial public offering on Wednesday, July 14th 2021. The company issued 4,687,500 shares at $15.00-$17.00 per share. How do I buy shares of Sera Prognostics? Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sera Prognostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sera Prognostics investors own include Meta Platforms (META), JPMorgan Chase & Co. (JPM), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD). Company Calendar Last Earnings5/06/2026Today7/30/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNASDAQ:SERA CIK1534969 Webwww.seraprognostics.com Phone801-990-0520FaxN/AEmployees120Year Founded2008Price Target and Rating Average Price Target for Sera Prognostics$5.50 High Price Target$6.00 Low Price Target$5.00 Potential Upside/Downside+161.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$31.93 million Net Margins-56,385.97% Pretax Margin-56,385.96% Return on Equity-41.02% Return on Assets-30.95% Debt Debt-to-Equity RatioN/A Current Ratio2.12 Quick Ratio2.12 Sales & Book Value Annual Sales$80 thousand Price / Sales1,027.95 Cash FlowN/A Price / Cash FlowN/A Book Value$1.94 per share Price / Book1.08Miscellaneous Outstanding Shares39,160,000Free Float34,734,000Market Cap$82.24 million OptionableOptionable Beta0.97 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:SERA) was last updated on 7/30/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredBREAKING: Bill Gates Says It’s “Worth 10 Microsofts”Nvidia is up 203% this year. Microsoft, Amazon, Apple, and Alphabet have each surged between 36% and 62%. But ...Traders Agency | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy Biggest Setup in 31 Years Started in RiyadhOn June 9, 2024, a 50-year pact between Washington and Riyadh quietly expired, cracking one of the hidden pill...Golden Portfolio | SponsoredSell SpaceX Now. Buy This Instead.Rob Spivey traveled to SpaceX's Starbase, Texas headquarters to uncover what Wall Street missed in the company...Altimetry | SponsoredThis tiny piece of glass could be bigger than GPUsA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...Brownstone Research | SponsoredThis under $7 stock could be.Just one mile from SpaceX's launchpad sits a small company doing something SpaceX can't - and it still trades ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sera Prognostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sera Prognostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
